{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-26-000204","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2026-05-13T20:03:13+00:00","discovered_at":"2026-05-13T20:04:00.498130+00:00","generated_at":"2026-05-13T22:18:21.632578+00:00","sec_items":["5.02","5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vertex shareholders approve 2026 Stock Plan, all director nominees, and shareholder written consent proposal","bullets":["All 10 director nominees elected; CEO Reshma Kewalramani received ~221.9M votes.","Shareholders ratified Ernst & Young as independent auditor for 2026 (223.5M for).","Advisory say-on-pay passed with 207.9M votes for vs. 14.5M against.","2026 Stock and Option Plan approved (216.1M for, 6.5M against), replacing 2013 plan.","Shareholder proposal for right to act by written consent passed (126.9M for vs. 95.8M against)."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-26-000204","json":"https://secwatch.observer/filing/0000875320-26-000204.json","markdown":"https://secwatch.observer/filing/0000875320-26-000204.md","text":"https://secwatch.observer/filing/0000875320-26-000204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000204/0000875320-26-000204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000204/vrtx-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T22:18:21.632578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}